In the current epidemiological context in France and given the still too limited data available to date concerning the VLA2001 vaccine, HAS considers that the integration of the VLA2001 vaccine into the current primary vaccination strategy is not justified.
Consequently, HAS does not currently recommend its use as a primary vaccination in the current vaccination strategy against Covid-19, given the availability of alternatives.
HAS recalls that, in accordance with the current vaccination strategy, primary vaccination against Covid-19 is accessible to all, from the age of 5. Primary vaccination is done, when possible, with an mRNA vaccine (Comirnaty or Spikevax). For people under 30, only the Comirnaty vaccine is recommended.
In addition, for people reluctant to this type of vaccine and those who cannot benefit from it (contraindications), HAS considers that the Nuvaxovid (from 18 years old) and Jcovden (from 55 years old) vaccines – which use different technologies – represent an effective alternative.
- Recommendation
- Europe
- France
- COVID-19
